The role of B lymphocytes in the development of Parkinson’s disease and its associated dementia.
Award Number
106565/Z/14/AStatus / Stage
CompletedDates
1 May 2015 -31 August 2018
Duration (calculated)
03 years 03 monthsFunder(s)
Wellcome TrustFunding Amount
£22,027.00Contracted Centre
University of CambridgePrincipal Investigator
Dr Kirsten ScottPI ORCID
0000-0003-3121-5963WHO Catergories
Understanding Underlying DiseaseDisease Type
Parkinson's DementiaCPEC Review Info
Reference ID | 310 |
---|---|
Researcher | Reside Team |
Published | 12/06/2023 |
Data
Award Number | 106565/Z/14/A |
---|---|
Status / Stage | Completed |
Start Date | 20150501 |
End Date | 20180831 |
Duration (calculated) | 03 years 03 months |
Contracted Centre | University of Cambridge |
Funding Amount | £22,027.00 |
Abstract
Parkinson’s disease (PD) is common, affecting between 2-3% of people over the age of 65 with over half of patients developing dementia within ten years. This causes a decline in function and often leads to nursing home care. The involvement of the immune system in PO has been well described but it remains unclear whether this is an epiphenomenon. I hypothesise that the immune response to PO associated pathology contributes to disease progression, increasing the risk of dementia. My PhD will look at the role played by 8 lymphocytes as most research has focused on T lymphocytes or the innate immune system. I aim to characterise the 8 lymphocyte response associated with alpha synuclein pathology in both the mouse and human brain and to identify whether there are perturbations in the systemic 8 cell compartment in patients at high risk of dementia versus those who have a low risk. Using two mouse models of PO I will manipulate B cells to see whether 8cell depletion, antibody depletion or manipulation of 8 cell regulatory activity alters disease course thereby confirming causation in an animal model.